Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
AbbVie Inc. stock logo
ABBV
AbbVie
$201.31
-1.9%
$199.66
$153.58
$218.66
$356.11B0.615.77 million shs7.59 million shs
Mastercard Incorporated stock logo
MA
Mastercard
$530.15
-3.1%
$551.87
$428.86
$582.23
$483.35B1.12.55 million shs3.44 million shs
Morgan Stanley stock logo
MS
Morgan Stanley
$107.70
-9.7%
$128.42
$85.01
$142.03
$173.70B1.356.60 million shs15.18 million shs
A Guide To High-Short-Interest Stocks Cover

MarketBeat's analysts have just released their top five short plays for April 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
AbbVie Inc. stock logo
ABBV
AbbVie
-0.56%+1.87%-3.00%+14.21%+13.40%
Mastercard Incorporated stock logo
MA
Mastercard
-0.10%-0.27%-4.66%+4.83%+14.22%
Morgan Stanley stock logo
MS
Morgan Stanley
+3.05%-2.31%-7.39%-4.35%+28.73%
Remove Ads
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
AbbVie Inc. stock logo
ABBV
AbbVie
4.4635 of 5 stars
2.53.03.33.93.42.51.3
Mastercard Incorporated stock logo
MA
Mastercard
4.7696 of 5 stars
3.53.03.33.03.52.51.9
Morgan Stanley stock logo
MS
Morgan Stanley
4.8054 of 5 stars
3.23.04.22.43.42.52.5
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
AbbVie Inc. stock logo
ABBV
AbbVie
2.92
Moderate Buy$211.455.04% Upside
Mastercard Incorporated stock logo
MA
Mastercard
2.93
Moderate Buy$606.1114.33% Upside
Morgan Stanley stock logo
MS
Morgan Stanley
2.33
Hold$129.8720.58% Upside

Current Analyst Ratings Breakdown

Latest ABBV, MS, and MA Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
4/3/2025
Morgan Stanley stock logo
MS
Morgan Stanley
JPMorgan Chase & Co.
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetNeutral ➝ Neutral$129.00 ➝ $125.00
4/2/2025
Morgan Stanley stock logo
MS
Morgan Stanley
Bank of America
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$150.00 ➝ $144.00
4/1/2025
Morgan Stanley stock logo
MS
Morgan Stanley
Evercore ISI
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOutperform ➝ Outperform$150.00 ➝ $138.00
3/28/2025
Morgan Stanley stock logo
MS
Morgan Stanley
Wells Fargo & Company
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetEqual Weight ➝ Equal Weight$142.00 ➝ $130.00
3/25/2025
Morgan Stanley stock logo
MS
Morgan Stanley
JPMorgan Chase & Co.
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetNeutral ➝ Neutral$124.00 ➝ $129.00
3/24/2025
Morgan Stanley stock logo
MS
Morgan Stanley
Citigroup
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetNeutral ➝ Neutral$135.00 ➝ $125.00
3/19/2025
Morgan Stanley stock logo
MS
Morgan Stanley
The Goldman Sachs Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetNeutral ➝ Neutral$144.00 ➝ $126.00
3/17/2025
AbbVie Inc. stock logo
ABBV
AbbVie
Erste Group Bank
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeStrong-Buy
3/17/2025
Morgan Stanley stock logo
MS
Morgan Stanley
Erste Group Bank
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeStrong-Buy ➝ Hold
3/10/2025
Mastercard Incorporated stock logo
MA
Mastercard
Tigress Financial
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingStrong-Buy ➝ Strong-Buy
3/5/2025
AbbVie Inc. stock logo
ABBV
AbbVie
Wells Fargo & Company
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOverweight ➝ Overweight$210.00 ➝ $240.00
(Data available from 4/3/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
AbbVie Inc. stock logo
ABBV
AbbVie
$56.33B6.32$14.88 per share13.53$1.90 per share105.95
Mastercard Incorporated stock logo
MA
Mastercard
$28.17B17.16$16.75 per share31.65$7.15 per share74.15
Morgan Stanley stock logo
MS
Morgan Stanley
$57.62B3.01$6.74 per share15.97$55.58 per share1.94
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
AbbVie Inc. stock logo
ABBV
AbbVie
$4.28B$2.4083.8814.401.627.59%296.28%12.65%4/25/2025 (Estimated)
Mastercard Incorporated stock logo
MA
Mastercard
$12.87B$13.8938.1728.492.3745.71%188.47%30.05%4/29/2025 (Estimated)
Morgan Stanley stock logo
MS
Morgan Stanley
$13.39B$7.9413.5611.421.1812.48%14.39%1.09%4/15/2025 (Estimated)

Latest ABBV, MS, and MA Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
4/25/2025N/A
AbbVie Inc. stock logo
ABBV
AbbVie
$2.51N/AN/AN/A$12.91 billionN/A
4/15/2025N/A
Morgan Stanley stock logo
MS
Morgan Stanley
$2.22N/AN/AN/A$16.81 billionN/A
1/31/2025Q4 24
AbbVie Inc. stock logo
ABBV
AbbVie
$2.98$2.16-$0.82-$0.02$14.81 billionN/A
1/30/2025Q4 2024
Mastercard Incorporated stock logo
MA
Mastercard
$3.71$3.82+$0.11$3.64$7.38 billionN/A
1/16/2025Q4 24
Morgan Stanley stock logo
MS
Morgan Stanley
$1.54$2.22+$0.68$2.22$15.03 billion$16.23 billion
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
AbbVie Inc. stock logo
ABBV
AbbVie
$6.563.26%+6.04%273.33%53 Years
Mastercard Incorporated stock logo
MA
Mastercard
$3.040.57%+14.82%21.89%13 Years
Morgan Stanley stock logo
MS
Morgan Stanley
$3.703.44%+19.13%46.60%12 Years

Latest ABBV, MS, and MA Dividends

AnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
2/13/2025
AbbVie Inc. stock logo
ABBV
AbbVie
quarterly$1.643.4%4/15/20254/15/20255/15/2025
2/10/2025
Mastercard Incorporated stock logo
MA
Mastercard
quarterly$0.760.54%4/9/20254/9/20255/9/2025
1/16/2025
Morgan Stanley stock logo
MS
Morgan Stanley
quarterly$0.92502.82%1/31/20251/31/20252/14/2025
(Data available from 1/1/2013 forward)
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
AbbVie Inc. stock logo
ABBV
AbbVie
17.94
0.66
0.55
Mastercard Incorporated stock logo
MA
Mastercard
2.68
1.03
1.03
Morgan Stanley stock logo
MS
Morgan Stanley
3.14
0.80
0.80

Institutional Ownership

CompanyInstitutional Ownership
AbbVie Inc. stock logo
ABBV
AbbVie
70.23%
Mastercard Incorporated stock logo
MA
Mastercard
97.28%
Morgan Stanley stock logo
MS
Morgan Stanley
84.19%

Insider Ownership

CompanyInsider Ownership
AbbVie Inc. stock logo
ABBV
AbbVie
0.08%
Mastercard Incorporated stock logo
MA
Mastercard
0.10%
Morgan Stanley stock logo
MS
Morgan Stanley
0.24%
CompanyEmployeesShares OutstandingFree FloatOptionable
AbbVie Inc. stock logo
ABBV
AbbVie
50,0001.77 billion1.76 billionOptionable
Mastercard Incorporated stock logo
MA
Mastercard
29,900911.71 million916.91 millionOptionable
Morgan Stanley stock logo
MS
Morgan Stanley
82,4001.61 billion1.61 billionOptionable

Recent News About These Companies

Morgan Stanley price target lowered to $125 from $129 at JPMorgan
Why Morgan Stanley Stock Sank Today
Insider Sale: COO of $AAPL Sells 17,292 Shares
Insider Purchase: Director at $APA Buys 75,000 Shares
Insider Sale: Director at $NA Sells 11,743 Shares
New Analyst Forecast: $MSFT Given 'Reduce' Rating
Morgan Stanley Upgrades Block (XYZ) Despite Stock Dip

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
AbbVie stock logo

AbbVie NYSE:ABBV

$201.31 -3.88 (-1.89%)
Closing price 03:59 PM Eastern
Extended Trading
$202.10 +0.79 (+0.39%)
As of 07:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; Elahere to treat cancer; and Venclexta/Venclyxto to treat blood cancers. It also provides facial injectables, plastics and regenerative medicine, body contouring, and skincare products; botox therapeutic; Vraylar for depressive disorder; Duopa and Duodopa to treat advanced Parkinson's disease; Ubrelvy for the acute treatment of migraine in adults; and Qulipta for episodic and chronic migraine. In addition, the company offers Ozurdex for eye diseases; Lumigan/Ganfort and Alphagan/Combigan for the reduction of elevated intraocular pressure in patients with open angle glaucoma or ocular hypertension; Restasis to increase tear production; and other eye care products. Further, it provides Mavyret/Maviret to treat chronic hepatitis C virus genotype 1-6 infection; Creon, a pancreatic enzyme therapy; Lupron to treat advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; and Synthroid for hypothyroidism. It has collaborations with Calico Life Sciences LLC; REGENXBIO Inc.; Janssen Biotech, Inc.; and Genentech, Inc., as well as collaboration with Tentarix Biotherapeutics, LP to develop conditionally-active and multi-specific biologics for oncology and immunology. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.

Mastercard stock logo

Mastercard NYSE:MA

$530.15 -17.23 (-3.15%)
Closing price 03:59 PM Eastern
Extended Trading
$531.29 +1.14 (+0.22%)
As of 07:56 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Mastercard Incorporated, a technology company, provides transaction processing and other payment-related products and services in the United States and internationally. The company offers integrated products and value-added services for account holders, merchants, financial institutions, digital partners, businesses, governments, and other organizations, such as programs that enable issuers to provide consumers with credits to defer payments; payment products and solutions that allow its customers to access funds in deposit and other accounts; prepaid programs services; and commercial credit, debit, and prepaid payment products and solutions. It also provides solutions that enable businesses or governments to make payments to businesses, including Virtual Card Number, which is generated dynamically from a physical card and leverages the credit limit of the funding account; a platform to optimize supplier payment enablement campaigns for financial institutions; and treasury intelligence platform that offers corporations with recommendations to enhance working capital performance and accelerate spend on cards. In addition, the company offers Mastercard Send, which partners with digital messaging and payment platforms to enable consumers to send money directly within applications to other consumers; and Mastercard Cross-Border Services enables a range of payment flows through a distribution network with a single point of access to send and receive money globally through various channels, including bank accounts, mobile wallets, cards, and cash payouts. Further, it provides cyber and intelligence solutions; insights and analytics, consulting, marketing, loyalty, processing, and payment gateway solutions for e-commerce merchants; and open banking and digital identity services. The company offers payment solutions and services under the MasterCard, Maestro, and Cirrus name. Mastercard Incorporated was founded in 1966 and is headquartered in Purchase, New York.

Morgan Stanley stock logo

Morgan Stanley NYSE:MS

$107.70 -11.57 (-9.70%)
Closing price 03:59 PM Eastern
Extended Trading
$108.44 +0.74 (+0.69%)
As of 07:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Morgan Stanley, a financial holding company, provides various financial products and services to corporations, governments, financial institutions, and individuals in the Americas, Europe, the Middle East, Africa, and Asia. It operates through Institutional Securities, Wealth Management, and Investment Management segments. The Institutional Securities segment offers capital raising and financial advisory services, including services related to the underwriting of debt, equity, and other securities, as well as advice on mergers and acquisitions, restructurings, real estate, and project finance. This segment also provides equity and fixed income products comprising sales, financing, prime brokerage, and market-making services; foreign exchange and commodities; corporate and commercial real estate loans, commercial mortgage and secured lending facilities, and financing for sales and trading customers, and asset-backed and mortgage lending; and wealth management services, investment, and research services. The Wealth Management segment offers financial advisor-led brokerage, custody, administrative, and investment advisory services; self-directed brokerage services; financial and wealth planning services; workplace services, including stock plan administration; annuity and insurance products; securities-based lending, residential real estate loans, and other lending products; banking; and retirement plan services to individual investors and small to medium-sized businesses and institutions. The Investment Management segment provides equity, fixed income, alternatives and solutions, and liquidity and overlay services to benefit/defined contribution plans, foundations, endowments, government entities, sovereign wealth funds, insurance companies, third-party fund sponsors, corporations, and individuals through institutional and intermediary channels. The company was founded in 1924 and is headquartered in New York, New York.